Holen Sie sich die Stockscreener-App
191.41
1.31%
-2.545
Schlusskurs vom Vortag:
$193.95
Offen:
$191.57
24-Stunden-Volumen:
553.73K
Relative Volume:
0.27
Marktkapitalisierung:
$41.03B
Einnahmen:
$742.00K
Nettoeinkommen (Verlust:
$-1.37B
KGV:
-27.06
EPS:
-7.0731
Netto-Cashflow:
$-1.07B
1W Leistung:
-4.24%
1M Leistung:
-6.07%
6M Leistung:
+40.43%
1J Leistung:
+292.63%
1-Tages-Spanne:
$190.20
$193.61
1-Wochen-Bereich:
$180.49
$203.50
52-Wochen-Spanne:
$47.28
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, MRNA, REGN, ARGX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
191.41 | 41.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 125.67B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
211.19 | 84.31B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
756.06 | 77.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.61 | 50.79B | 4.16B | 1.29B | 734.26M | 19.58 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-24 | Fortgesetzt | Goldman | Buy |
| 2026-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-05-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-05-18 | Fortgesetzt | Truist | Buy |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-02-27 | Fortgesetzt | UBS | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
About 3% of U.S. patients with metastatic pancreatic cancer survive five years. A drug pair starts testing in patients. - Stock Titan
Revolution Medicines (NasdaqGS:RVMD) Stock Forecast & Analyst Predictions - Simply Wall Street
Revolution Medicines’ CDO Sandler sells $1.2m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 October By Investing.com - Investing.com UK
Revolution Medicines SVP Cislini sells $158,599 in shares By Investing.com - Investing.com Nigeria
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com South Africa
Revolution Medicines SVP Cislini sells $158,599 in shares - Investing.com
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com UK
Revolution Medicines SVP Jeff Cislini Sells 765 Shares Under 10b5-1 Trading Plan - Kalkine Media
Revolution Medicines (RVMD) counsel Jeff Cislini sold 765 shares at $207.3201 each under a trading plan. - Stock Titan
6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD). - Stock Titan
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com South Africa
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com Nigeria
Revolution Medicines officer Mancini sells $743k in stock - Investing.com
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com UK
Stock options are the source of 9,363 shares a Revolution Medicines (RVMD) officer proposes to sell. - Stock Titan
Revolution Medicines director Elizabeth Anderson sells $1.96m in stock - Investing.com
Revolution Medicines (RVMD) director exercises options for 5,070 shares and sells 10,143 shares. - Stock Titan
After three earlier sales, an officer proposes selling 587 more Revolution Medicines (RVMD) shares. - Stock Titan
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes - Yahoo Finance
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Canada
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Revolution Medicines chief development officer sells $67,940 in stock - Investing.com
Revolution Medicines officer sells $353,449 in shares - Investing.com
Revolution Medicines COO Margaret Horn sells $989,612 of common stock - Investing.com
Revolution Medicines’ senior advisor sells $1.1m in stock - Investing.com
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Revolution Medicines CFO Jack Anders sells $807,513 in stock - Investing.com
Revolution Medicines (RVMD) exec sells 1,774 shares, keeps 39,575 RSUs - Stock Titan
Revolution Medicines (RVMD) legal chief makes pre-set stock sale for taxes - Stock Titan
Revolution Medicines (RVMD) insider adds new sale after multimillion-dollar trades - Stock Titan
Revolution Medicines (RVMD) CFO sells shares under tax-driven plan - Stock Titan
Officer at Revolution Medicines (RVMD) plans 331-share sale - Stock Titan
Revolution Medicines officer plans $484K sale | RVMD SEC FilingForm 144 - Stock Titan
Officer at Revolution Medicines (NASDAQ: RVMD) plans 4,830-share stock sale after RSU vesting - Stock Titan
Over $16M in recent stock sales as Revolution Medicines (NASDAQ: RVMD) filer Mark A. Goldsmith plans another trade - Stock Titan
Revolution Medicines (RVMD) exec exercises options, sells stock - Stock Titan
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com Australia
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com Canada
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Revolution Medicines Inc-Aktie (RVMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ALAN SANDLER | Officer |
Sep 29 '26 |
Proposed Sale |
201.74 |
6,309 |
1,272,778 |
0 |
| Sandler Alan B. | Chief Development Officer |
Sep 29 '26 |
Sale |
202.14 |
6,309 |
1,275,294 |
52,559 |
| Mancini Anthony | See Remarks |
Sep 25 '26 |
Option Exercise |
33.62 |
3,121 |
104,928 |
42,886 |
| Mancini Anthony | See Remarks |
Sep 25 '26 |
Sale |
200.54 |
3,121 |
625,885 |
39,765 |
| ANTHONY MANCINI | Officer |
Sep 25 '26 |
Proposed Sale |
199.86 |
9,363 |
1,871,289 |
0 |
| Cislini Jeff | SVP & General Counsel |
Sep 25 '26 |
Sale |
207.32 |
765 |
158,600 |
51,776 |
| ANTHONY MANCINI | Officer |
Sep 24 '26 |
Proposed Sale |
190.74 |
587 |
111,964 |
0 |
| Mancini Anthony | See Remarks |
Sep 24 '26 |
Sale |
200.00 |
587 |
117,400 |
39,765 |
| ANDERSON ELIZABETH M | Director |
Sep 22 '26 |
Sale |
193.04 |
10,143 |
1,958,016 |
4,333 |
| ANDERSON ELIZABETH M | Director |
Sep 22 '26 |
Option Exercise |
1.12 |
5,070 |
5,678 |
14,476 |
0.61%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):